SG11201809903WA - Method for purification and activation of botulinum neurotoxin - Google Patents

Method for purification and activation of botulinum neurotoxin

Info

Publication number
SG11201809903WA
SG11201809903WA SG11201809903WA SG11201809903WA SG11201809903WA SG 11201809903W A SG11201809903W A SG 11201809903WA SG 11201809903W A SG11201809903W A SG 11201809903WA SG 11201809903W A SG11201809903W A SG 11201809903WA SG 11201809903W A SG11201809903W A SG 11201809903WA
Authority
SG
Singapore
Prior art keywords
international
ntnha
bont
rule
protein
Prior art date
Application number
SG11201809903WA
Other languages
English (en)
Inventor
Min Dong
Sulyman Barkho
Liang Tao
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of SG11201809903WA publication Critical patent/SG11201809903WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
SG11201809903WA 2016-05-16 2017-05-16 Method for purification and activation of botulinum neurotoxin SG11201809903WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662336958P 2016-05-16 2016-05-16
PCT/US2017/032985 WO2017201105A1 (fr) 2016-05-16 2017-05-16 Procédé de purification et d'activation de la neurotoxine botulique

Publications (1)

Publication Number Publication Date
SG11201809903WA true SG11201809903WA (en) 2018-12-28

Family

ID=59014734

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809903WA SG11201809903WA (en) 2016-05-16 2017-05-16 Method for purification and activation of botulinum neurotoxin

Country Status (16)

Country Link
US (1) US11242515B2 (fr)
EP (1) EP3458472B1 (fr)
JP (1) JP7060522B2 (fr)
KR (1) KR102567311B1 (fr)
CN (1) CN109641941B (fr)
AU (1) AU2017268285B2 (fr)
BR (1) BR112018073591A2 (fr)
CA (1) CA3024331A1 (fr)
EA (1) EA201892643A1 (fr)
ES (1) ES2904269T3 (fr)
MX (1) MX2018014066A (fr)
SA (1) SA518400443B1 (fr)
SG (1) SG11201809903WA (fr)
UA (1) UA127310C2 (fr)
WO (1) WO2017201105A1 (fr)
ZA (1) ZA201807626B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2673910C2 (ru) * 2012-11-21 2018-12-03 Ипсен Байоинновейшн Лимитед Способ производства протеолитически процессированного полипептида
UA127310C2 (uk) * 2016-05-16 2023-07-19 Презідент Енд Феллоуз Оф Гарвард Колледж Спосіб очищення і активації ботулінічного нейротоксину
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
SE542539C2 (en) * 2018-02-26 2020-06-02 Toxotech Ab Chimeric botulinum neurotoxin heavy chain binding domain
WO2020129027A1 (fr) * 2018-12-21 2020-06-25 King Abdullah University Of Science And Technology Systèmes de purification par affinité fondés sur une pince coulissante, leurs procédés de fabrication et leur utilisation
CN110208411B (zh) * 2019-06-10 2021-12-24 浙江龙传生物医药科技有限公司 用于药物代谢检测的羧酸酯酶抑制剂制剂
CN114958887A (zh) * 2021-02-26 2022-08-30 重庆誉颜制药有限公司 一种经修饰的毒素多肽的制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
CA1340522C (fr) 1987-03-10 1999-05-04 Heinz Dobeli Proteins hybrides renfermant des histidines voisines pour une purification amelioree
US5654176A (en) 1987-05-28 1997-08-05 Amrad Corporation Limited Fusion proteins containing glutathione-s-transferase
US5599903A (en) 1992-04-03 1997-02-04 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
KR20030060150A (ko) * 2002-01-07 2003-07-16 (주)메디톡스 클로스트리디움 보툴리눔 ａ형 독소를 정제하는 방법
NZ537120A (en) * 2002-05-31 2008-07-31 Univ Jefferson Compositions and methods for transepithelial molecular transport
US7148041B2 (en) 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US8137924B2 (en) * 2003-12-19 2012-03-20 Wisconsin Alumni Research Foundation Method and compositions for detecting botulinum neurotoxin
JP2008532549A (ja) * 2005-03-15 2008-08-21 アラーガン、インコーポレイテッド 内因性クロストリジウム毒素受容体系に対する増大した標的能力を有する修飾クロストリジウム毒素
US7985554B2 (en) * 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof
JP2009132686A (ja) * 2007-10-26 2009-06-18 Okayama Univ ボツリヌス毒素由来のポリペプチド及びボツリヌス毒素の検出方法
JP2010037253A (ja) * 2008-08-04 2010-02-18 Chemo Sero Therapeut Res Inst ボツリヌス毒素に対するモノクローナル抗体および該抗体を用いたボツリヌス神経毒素精製方法
US8771707B2 (en) * 2008-09-30 2014-07-08 Wisconsin Alumni Research Foundation Botulinum neurotoxin E receptors and uses thereof
RU2012129557A (ru) * 2009-12-16 2014-01-27 Аллерган, Инк. МОДИФИЦИРОВАННЫЕ ТОКСИНЫ Clostridial, СОДЕРЖАЩИЕ ИНТЕГРИРОВАННЫЙ САЙТ-СВЯЗЫВАЮЩИЙ ДОМЕН ПРОТЕАЗНОГО РАСЩЕПЛЕНИЯ
HUE033172T2 (en) 2011-05-19 2017-11-28 Ipsen Bioinnovation Ltd A method for producing proteolytically processed polypeptides
JP6336970B2 (ja) * 2012-05-30 2018-06-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたボツリヌス神経毒素
KR101339349B1 (ko) * 2013-08-02 2013-12-09 주식회사 대웅 보툴리눔 독소의 제조방법
UA127310C2 (uk) 2016-05-16 2023-07-19 Презідент Енд Феллоуз Оф Гарвард Колледж Спосіб очищення і активації ботулінічного нейротоксину
CN109476713A (zh) * 2016-06-08 2019-03-15 儿童医学中心公司 工程改造的肉毒杆菌神经毒素
IL298102A (en) * 2016-07-08 2023-01-01 Childrens Medical Center A new botulinum neurotoxin and its derivatives
KR102463881B1 (ko) * 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법
DK3529616T3 (da) * 2016-10-20 2023-12-11 Harvard College In vitro- og cellebaserede assays til måling af aktiviteten af botulinum-neurotoksiner

Also Published As

Publication number Publication date
EP3458472B1 (fr) 2021-10-20
JP2019518447A (ja) 2019-07-04
BR112018073591A2 (pt) 2019-03-19
WO2017201105A1 (fr) 2017-11-23
CN109641941A (zh) 2019-04-16
EP3458472A1 (fr) 2019-03-27
CA3024331A1 (fr) 2017-11-23
KR20190015240A (ko) 2019-02-13
JP7060522B2 (ja) 2022-04-26
AU2017268285B2 (en) 2021-07-29
US11242515B2 (en) 2022-02-08
SA518400443B1 (ar) 2022-06-22
AU2017268285A1 (en) 2018-11-29
CN109641941B (zh) 2023-06-16
EA201892643A1 (ru) 2019-06-28
US20190153418A1 (en) 2019-05-23
KR102567311B1 (ko) 2023-08-16
ES2904269T3 (es) 2022-04-04
MX2018014066A (es) 2019-04-04
ZA201807626B (en) 2023-10-25
UA127310C2 (uk) 2023-07-19

Similar Documents

Publication Publication Date Title
SG11201809903WA (en) Method for purification and activation of botulinum neurotoxin
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201807912SA (en) Vaccine against rsv
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201909646TA (en) Trem2 antigen binding proteins and uses thereof
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201807025SA (en) Crispr/cas systems for c-1 fixing bacteria
SG11201906341XA (en) Improved serum albumin binders
SG11201906264YA (en) Improved serum albumin binders
SG11201811643TA (en) Compounds and methods for modulating rna function
SG11202000105QA (en) Anti-cd166 antibodies and uses thereof
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201906319XA (en) Compositions and methods for the depletion of cd137+ cells
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201909011PA (en) Niraparib compositions
SG11201906961UA (en) Polypeptide variants and uses thereof
SG11201907434RA (en) Compositions and methods for immunooncology
SG11201909602TA (en) Compositions and methods involving probiotic molecules
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof